Treatment of snake envenomations by a new polyvalent antivenom composed of highly purified F(ab')2 : results of a clinical trial in northern Cameroon /Chippaux, Jean-Philippe Lang, J. Amadi-Eddine, S. Fagot, P. Le Mener, V. SERPENT MORSURE VENIN TRAITEMENT MEDICAL ANTICORPS ENFANT ADULTE ESSAI CLINIQUE FAV-AFRICA EFFET INDESIRABLE A clinical trail was conducted in 2 health centers in northern Cameroon to assess the safety and efficacy of a new polyvalent antivenom composed of higly purified and pasteurized F(ab')2 (FAV-Africa). Forty-six patients with objective signs of envenomation, including 67% with hemorrhage, were included in the study. Each patient received at least 20 ml of FAV-Africa by direct, slow intravenous injection ; 172 10-ml ampules were administered. All patients were clinically cured after treatment. Two patients (4.3%) showed minor immediate adverse events that may have been related to FAV-Africa (induration, light-headedness) ; no other treatment-related adverse event occurred. No patient had serum sickness. This trial confirms the safety of FAV-Africa administered by intravenous injection and its efficacy in the treatment of snake envenomations in sub-Sahara Africa. (Résumé d'auteur) 1999 text https://www.documentation.ird.fr/hor/fdi:010021757 fdi:010021757 Chippaux Jean-Philippe, Lang J., Amadi-Eddine S., Fagot P., Le Mener V.. Treatment of snake envenomations by a new polyvalent antivenom composed of highly purified F(ab')2 : results of a clinical trial in northern Cameroon. 1999, 61 (6), 1017-1018 EN AFRIQUE SUBSAHARIENNE CAMEROUN